IRIS
SONCINI, DEBORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.487
AS - Asia 304
SA - Sud America 31
NA - Nord America 27
AF - Africa 4
Totale 5.853
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.484
SG - Singapore 135
CN - Cina 75
VN - Vietnam 73
BR - Brasile 21
US - Stati Uniti d'America 18
HK - Hong Kong 10
MX - Messico 7
AR - Argentina 3
EC - Ecuador 3
ID - Indonesia 3
IQ - Iraq 3
PY - Paraguay 3
MA - Marocco 2
PA - Panama 2
ZA - Sudafrica 2
AT - Austria 1
BD - Bangladesh 1
IN - India 1
KH - Cambogia 1
LB - Libano 1
MD - Moldavia 1
UA - Ucraina 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 5.853
Salva come PNG Salva come JPEG
Città #
Genova 2.844
Genoa 1.800
Rapallo 497
Vado Ligure 329
Singapore 54
Ho Chi Minh City 32
Beijing 30
Hanoi 17
Ashburn 14
Hong Kong 10
Bordighera 7
Mexico City 5
Can Tho 4
Da Nang 4
Rome 3
Tianjin 3
Cuenca 2
Panama City 2
São Paulo 2
Agadir 1
Alcobaça 1
Alfenas 1
Araçuaí 1
Armazém 1
Asunción 1
Baghdad 1
Basra 1
Bekasi 1
Belo Horizonte 1
Buenos Aires 1
Bình Dương 1
Bắc Ninh 1
Campina Grande 1
Caroebe Municipality 1
Casablanca 1
Chapada Gaúcha 1
Chicago 1
Ciudad del Este 1
Contendas do Sincorá 1
Cuautitlán Izcalli 1
Curuzú Cuatiá 1
Durban 1
Formosa 1
Gustavo Adolfo Madero 1
Haiphong 1
Hải Dương 1
Karbala 1
Lambaré 1
Long An 1
Ludhiana 1
Montevideo 1
Nam Định 1
Nha Trang 1
Orem 1
Padang 1
Phú Thọ 1
Phủ Lý 1
Pimenta Bueno 1
Quito 1
Quảng Ngãi 1
Ribeirão Preto 1
Rio de Janeiro 1
Santa Bárbara 1
Santo André 1
Saquarema 1
Sebokeng 1
Sidon 1
São Carlos 1
São José do Rio Preto 1
Tashkent 1
Thái Nguyên 1
Ubá 1
Vitória da Conquista 1
Vĩnh Tường 1
Totale 5.714
Salva come PNG Salva come JPEG
Nome #
1222 POSTER Chemical Screening for Potentiators of Lapatinib Activity in Human Breast Cancer 232
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 228
1221 POSTER Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 224
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 219
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 214
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 193
Ras-induced resistance to lapatinib is overcome by MEK inhibition 184
SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects 183
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 174
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 174
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 170
CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. 169
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 165
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 162
Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments. Concordance with experimental results. 160
Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 155
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. 154
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 152
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 152
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 142
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 138
Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. 134
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 132
Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors 130
Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. 127
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 126
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 124
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. 122
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 122
Chemical Screening for Potentiators of Lapatinib Activity in Human Breast Cancer 121
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 112
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 111
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 96
Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. 94
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 94
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 91
Sirtuin 6 Regulates the Activation of the ATP/Purinergic Axis in Endothelial Cells 72
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis 69
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma 64
Targeting the immune microenvironment in Waldenström Macroglobulinemia via halting the CD40/CD40-ligand axis 61
Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies 59
EXTRACELLULAR NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) ARRESTS ENDOTHELIAL CELL PROLIFERATION 47
Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies 42
The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS 32
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 32
Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1 11
Totale 5.969
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.081
article - articoli 18.710
book - libri 0
conference - conferenze 371
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.162
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021224 0 0 0 0 0 27 28 39 26 44 41 19
2021/2022466 15 21 35 74 18 36 22 97 20 39 28 61
2022/2023603 55 59 10 92 101 72 8 43 83 9 63 8
2023/2024358 10 28 15 52 34 78 14 45 13 3 15 51
2024/20251.102 37 61 16 81 102 104 91 219 41 73 133 144
2025/2026982 265 81 141 198 282 15 0 0 0 0 0 0
Totale 5.969